{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:42:17Z","timestamp":1778038937999,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-025-01866-7","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T05:35:58Z","timestamp":1753680958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of GLP1RAs with risk of chronic obstructive pulmonary disease: evidence from drug target Mendelian randomization"],"prefix":"10.1186","volume":"17","author":[{"given":"Sijia","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaohui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"4","key":"1866_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of Glucagon-like Peptide-1. Cell Metabol. 2018;27(4):740\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metabol"},{"issue":"9548","key":"1866_CR2","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/s0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (London England). 2006;368(9548):1696\u2013705. https:\/\/doi.org\/10.1016\/s0140-6736(06)69705-5","journal-title":"Lancet (London England)"},{"issue":"20","key":"1866_CR3","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: A review. JAMA. 2023;330(20):2000\u201315. https:\/\/doi.org\/10.1001\/jama.2023.19897","journal-title":"JAMA"},{"issue":"6","key":"1866_CR4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/obr.12839","volume":"20","author":"GA Christou","year":"2019","unstructured":"Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Reviews: Official J Int Association Study Obes. 2019;20(6):805\u201315. https:\/\/doi.org\/10.1111\/obr.12839","journal-title":"Obes Reviews: Official J Int Association Study Obes"},{"issue":"15","key":"1866_CR5","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with Obesity-Related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2313917","journal-title":"N Engl J Med"},{"issue":"10456","key":"1866_CR6","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/s0140-6736(24)01643-x","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet (London England). 2024;404(10456):949\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(24)01643-x","journal-title":"Lancet (London England)"},{"issue":"24","key":"1866_CR7","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"issue":"2","key":"1866_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"issue":"4","key":"1866_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","volume":"17","author":"RZ Alicic","year":"2021","unstructured":"Alicic RZ, Cox EJ, Neumiller JJ, Tuttle KR. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat Rev Nephrol. 2021;17(4):227\u201344. https:\/\/doi.org\/10.1038\/s41581-020-00367-2","journal-title":"Nat Rev Nephrol"},{"key":"1866_CR10","doi-asserted-by":"publisher","unstructured":"Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow ND et al. Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer\u2019s & dementia: the journal of the Alzheimer\u2019s Association. 2024. https:\/\/doi.org\/10.1002\/alz.14313","DOI":"10.1002\/alz.14313"},{"issue":"10342","key":"1866_CR11","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/s0140-6736(22)00470-6","volume":"399","author":"SA Christenson","year":"2022","unstructured":"Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet (London England). 2022;399(10342):2227\u201342. https:\/\/doi.org\/10.1016\/s0140-6736(22)00470-6","journal-title":"Lancet (London England)"},{"issue":"2","key":"1866_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1183\/09031936.06.00056106","volume":"28","author":"FE Hargreave","year":"2006","unstructured":"Hargreave FE, Parameswaran K, Asthma. COPD and bronchitis are just components of airway disease. Eur Respir J. 2006;28(2):264\u20137. https:\/\/doi.org\/10.1183\/09031936.06.00056106","journal-title":"Eur Respir J"},{"issue":"9","key":"1866_CR13","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1111\/dom.15142","volume":"25","author":"J Su","year":"2023","unstructured":"Su J, Li M, Wan X, Yu H, Wan Y, Hang D, et al. Associations of diabetes, prediabetes and diabetes duration with the risk of chronic obstructive pulmonary disease: A prospective UK biobank study. Diabetes Obes Metab. 2023;25(9):2575\u201385. https:\/\/doi.org\/10.1111\/dom.15142","journal-title":"Diabetes Obes Metab"},{"key":"1866_CR14","doi-asserted-by":"publisher","unstructured":"Cooper DH, Akbarian N, Aaron SD, Luks V, Kendzerska T. Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review. Respir Med. 2025;108197. https:\/\/doi.org\/10.1016\/j.rmed.2025.108197","DOI":"10.1016\/j.rmed.2025.108197"},{"key":"1866_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/copd.S393323","volume":"18","author":"W Wang","year":"2023","unstructured":"Wang W, Mei A, Qian H, Li D, Xu H, Chen J, et al. The role of Glucagon-Like Peptide-1 receptor agonists in chronic obstructive pulmonary disease. Int J Chronic Obstr Pulm Dis. 2023;18:129\u201337. https:\/\/doi.org\/10.2147\/copd.S393323","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"2","key":"1866_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13539-011-0023-9","volume":"2","author":"M Lainscak","year":"2011","unstructured":"Lainscak M, von-Haehling S, Doehner W, Sarc I, Jeric T, Ziherl K, et al. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J cachexia Sarcopenia Muscle. 2011;2(2):81\u20136. https:\/\/doi.org\/10.1007\/s13539-011-0023-9","journal-title":"J cachexia Sarcopenia Muscle"},{"key":"1866_CR17","doi-asserted-by":"publisher","unstructured":"Tenda ED, Henrina J, Setiadharma A, Felix I, Yulianti M, Pitoyo CW, et al. The impact of body mass index on mortality in COPD: an updated dose-response meta-analysis. Eur Respiratory Review: Official J Eur Respiratory Soc. 2024;33(174). https:\/\/doi.org\/10.1183\/16000617.0261-2023","DOI":"10.1183\/16000617.0261-2023"},{"issue":"12","key":"1866_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1164\/rccm.202309-1671LE","volume":"208","author":"Q Li","year":"2023","unstructured":"Li Q, Chen Y, Jiang H, Xi Y, Wang J, Zhu X, et al. A daunting and challenging task to prove the effectiveness of reducing acute exacerbation in COPD patients with type 2 diabetes by GLP-1 receptor agonists. Am J Respir Crit Care Med. 2023;208(12):1345\u20136. https:\/\/doi.org\/10.1164\/rccm.202309-1671LE","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1866_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1159\/000531792","volume":"16","author":"S Yao","year":"2023","unstructured":"Yao S, Zeng L, Wang F, Chen K. Obesity paradox in lung diseases: what explains it?? Obes Facts. 2023;16(5):411\u201326. https:\/\/doi.org\/10.1159\/000531792","journal-title":"Obes Facts"},{"issue":"1","key":"1866_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","volume":"32","author":"GD Smith","year":"2003","unstructured":"Smith GD, Ebrahim S. Mendelian randomization\u2019: can genetic epidemiology contribute to Understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1\u201322. https:\/\/doi.org\/10.1093\/ije\/dyg070","journal-title":"Int J Epidemiol"},{"issue":"10","key":"1866_CR21","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/s41588-020-0682-6","volume":"52","author":"J Zheng","year":"2020","unstructured":"Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet. 2020;52(10):1122\u201331. https:\/\/doi.org\/10.1038\/s41588-020-0682-6","journal-title":"Nat Genet"},{"issue":"1","key":"1866_CR22","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","volume":"11","author":"AF Schmidt","year":"2020","unstructured":"Schmidt AF, Finan C, Gordillo-Mara\u00f1\u00f3n M, Asselbergs FW, Freitag DF, Patel RS, et al. Genetic drug target validation using Mendelian randomisation. Nat Commun. 2020;11(1):3255. https:\/\/doi.org\/10.1038\/s41467-020-16969-0","journal-title":"Nat Commun"},{"issue":"1","key":"1866_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13578-024-01214-8","volume":"14","author":"Y Yang","year":"2024","unstructured":"Yang Y, Chen B, Zheng C, Zeng H, Zhou J, Chen Y, et al. Association of glucose-lowering drug target and risk of Gastrointestinal cancer: a Mendelian randomization study. Cell Bioscience. 2024;14(1):36. https:\/\/doi.org\/10.1186\/s13578-024-01214-8","journal-title":"Cell Bioscience"},{"issue":"16","key":"1866_CR24","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1001\/jama.2021.18236","volume":"326","author":"VW Skrivankova","year":"2021","unstructured":"Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement. JAMA. 2021;326(16):1614\u201321. https:\/\/doi.org\/10.1001\/jama.2021.18236","journal-title":"JAMA"},{"issue":"1","key":"1866_CR25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41467-020-14389-8","volume":"11","author":"N Papadimitriou","year":"2020","unstructured":"Papadimitriou N, Dimou N, Tsilidis KK, Banbury B, Martin RM, Lewis SJ, et al. Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nat Commun. 2020;11(1):597. https:\/\/doi.org\/10.1038\/s41467-020-14389-8","journal-title":"Nat Commun"},{"issue":"9","key":"1866_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/s2213-2600(17)30293-x","volume":"5","author":"GBD 2015 Chronic Respiratory Disease Collaborators","year":"2017","unstructured":"GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and National deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990\u20132015: a systematic analysis for the global burden of disease study 2015. Lancet Respiratory Med. 2017;5(9):691\u2013706. https:\/\/doi.org\/10.1016\/s2213-2600(17)30293-x","journal-title":"Lancet Respiratory Med"},{"issue":"7944","key":"1866_CR27","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki MI, Karjalainen J, Palta P, Sipil\u00e4 TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508\u201318. https:\/\/doi.org\/10.1038\/s41586-022-05473-8","journal-title":"Nature"},{"key":"1866_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.3","volume":"4","author":"S Burgess","year":"2019","unstructured":"Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2019;4:186. https:\/\/doi.org\/10.12688\/wellcomeopenres.15555.3","journal-title":"Wellcome Open Res"},{"key":"1866_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae279","author":"KC Koskinas","year":"2024","unstructured":"Koskinas KC, Van Craenenbroeck EM, Antoniades C, Bl\u00fcher M, Gorter TM, Hanssen H, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur J Prev Cardiol. 2024. https:\/\/doi.org\/10.1093\/eurjpc\/zwae279","journal-title":"Eur J Prev Cardiol"},{"key":"1866_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2147\/copd.S350133","volume":"17","author":"AD Altintas-Dogan","year":"2022","unstructured":"Altintas-Dogan AD, Hilberg O, Hess S, Jensen TT, Bladbjerg EM, Juhl CB. Respiratory effects of treatment with a Glucagon-Like Peptide-1 receptor agonist in patients suffering from obesity and chronic obstructive pulmonary disease. Int J Chronic Obstr Pulm Dis. 2022;17:405\u201314. https:\/\/doi.org\/10.2147\/copd.S350133","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"19","key":"1866_CR31","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin CA, Khera AV, Kathiresan S, Mendelian Randomization. JAMA. 2017;318(19):1925\u20136. https:\/\/doi.org\/10.1001\/jama.2017.17219","journal-title":"JAMA"},{"key":"1866_CR32","doi-asserted-by":"publisher","first-page":"e069679","DOI":"10.1136\/bmj-2021-069679","volume":"378","author":"S Safiri","year":"2022","unstructured":"Safiri S, Carson-Chahhoud K, Noori M, Nejadghaderi SA, Sullman MJM, Ahmadian-Heris J, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990\u20132019: results from the global burden of disease study 2019. BMJ (Clinical Res ed). 2022;378:e069679. https:\/\/doi.org\/10.1136\/bmj-2021-069679","journal-title":"BMJ (Clinical Res ed)"},{"issue":"7","key":"1866_CR33","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jacc.2022.05.041","volume":"80","author":"DB Rosoff","year":"2022","unstructured":"Rosoff DB, Bell AS, Jung J, Wagner J, Mavromatis LA, Lohoff FW. Mendelian randomization study of PCSK9 and HMG-CoA reductase Inhibition and cognitive function. J Am Coll Cardiol. 2022;80(7):653\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2022.05.041","journal-title":"J Am Coll Cardiol"},{"key":"1866_CR34","doi-asserted-by":"publisher","first-page":"k601","DOI":"10.1136\/bmj.k601","volume":"362","author":"NM Davies","year":"2018","unstructured":"Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ (Clinical Res ed). 2018;362:k601. https:\/\/doi.org\/10.1136\/bmj.k601","journal-title":"BMJ (Clinical Res ed)"},{"issue":"1","key":"1866_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1465-9921-8-7","volume":"8","author":"MD Eisner","year":"2007","unstructured":"Eisner MD, Blanc PD, Sidney S, Yelin EH, Lathon PV, Katz PP, et al. Body composition and functional limitation in COPD. Respir Res. 2007;8(1):7. https:\/\/doi.org\/10.1186\/1465-9921-8-7","journal-title":"Respir Res"},{"key":"1866_CR36","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2147\/copd.S242009","volume":"15","author":"J Recio-Iglesias","year":"2020","unstructured":"Recio-Iglesias J, D\u00edez-Manglano J, L\u00f3pez-Garc\u00eda F, D\u00edaz-Peromingo JA, Almagro P, Varela-Aguilar JM. Management of the COPD patient with comorbidities: an experts recommendation document. Int J Chronic Obstr Pulm Dis. 2020;15:1015\u201337. https:\/\/doi.org\/10.2147\/copd.S242009","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"2","key":"1866_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","volume":"26","author":"JP Frias","year":"2017","unstructured":"Frias JP, Bastyr EJ 3rd, Vignati L, Tsch\u00f6p MH, Schmitt C, Owen K, et al. The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metabol. 2017;26(2):343\u2013e352342. https:\/\/doi.org\/10.1016\/j.cmet.2017.07.011","journal-title":"Cell Metabol"},{"issue":"10","key":"1866_CR38","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/j.biochi.2012.03.006","volume":"94","author":"N Ali-Assad","year":"2012","unstructured":"Ali-Assad N, Sood A. Leptin, adiponectin and pulmonary diseases. Biochimie. 2012;94(10):2180\u20139. https:\/\/doi.org\/10.1016\/j.biochi.2012.03.006","journal-title":"Biochimie"},{"issue":"5","key":"1866_CR39","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3349\/ymj.2008.49.5.804","volume":"49","author":"JH Shin","year":"2008","unstructured":"Shin JH, Kim JH, Lee WY, Shim JY. The expression of adiponectin receptors and the effects of adiponectin and leptin on airway smooth muscle cells. Yonsei Med J. 2008;49(5):804\u201310. https:\/\/doi.org\/10.3349\/ymj.2008.49.5.804","journal-title":"Yonsei Med J"},{"issue":"3","key":"1866_CR40","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.clnu.2022.01.015","volume":"41","author":"R Beijers","year":"2022","unstructured":"Beijers R, Franssen FME, Groenen MTJ, Spruit MA, Schols A. Physical and mental health profile of patients with the early-onset severe COPD phenotype: A cross-sectional analysis. Clin Nutr. 2022;41(3):653\u201360. https:\/\/doi.org\/10.1016\/j.clnu.2022.01.015","journal-title":"Clin Nutr"},{"key":"1866_CR41","doi-asserted-by":"publisher","unstructured":"Soriano JB, Polverino F, Cosio BG. What is early COPD and why is it important? The European respiratory journal. 2018;52(6). https:\/\/doi.org\/10.1183\/13993003.01448-2018","DOI":"10.1183\/13993003.01448-2018"},{"issue":"3","key":"1866_CR42","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jaci.2012.09.024","volume":"131","author":"M Kohler","year":"2013","unstructured":"Kohler M, Sandberg A, Kjellqvist S, Thomas A, Karimi R, Nyr\u00e9n S, et al. Gender differences in the Bronchoalveolar lavage cell proteome of patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):743\u201351. https:\/\/doi.org\/10.1016\/j.jaci.2012.09.024","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1866_CR43","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.2337\/db16-1009","volume":"66","author":"FP Zummo","year":"2017","unstructured":"Zummo FP, Cullen KS, Honkanen-Scott M, Shaw JAM, Lovat PE, Arden C. Glucagon-Like peptide 1 protects pancreatic \u03b2-Cells from death by increasing autophagic flux and restoring lysosomal function. Diabetes. 2017;66(5):1272\u201385. https:\/\/doi.org\/10.2337\/db16-1009","journal-title":"Diabetes"},{"issue":"4","key":"1866_CR44","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/15548627.2021.1956123","volume":"18","author":"FP Zummo","year":"2022","unstructured":"Zummo FP, Krishnanda SI, Georgiou M, O\u2019Harte FP, Parthsarathy V, Cullen KS, et al. Exendin-4 stimulates autophagy in pancreatic \u03b2-cells via the RAPGEF\/EPAC-Ca(2+)-PPP3\/calcineurin-TFEB axis. Autophagy. 2022;18(4):799\u2013815. https:\/\/doi.org\/10.1080\/15548627.2021.1956123","journal-title":"Autophagy"},{"issue":"2","key":"1866_CR45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/MCP.0b013e32835d903b","volume":"19","author":"F Kamil","year":"2013","unstructured":"Kamil F, Pinzon I, Foreman MG. Sex and race factors in early-onset COPD. Curr Opin Pulm Med. 2013;19(2):140\u20134. https:\/\/doi.org\/10.1097\/MCP.0b013e32835d903b","journal-title":"Curr Opin Pulm Med"},{"issue":"6","key":"1866_CR46","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.2337\/dc20-1794","volume":"44","author":"Y Albogami","year":"2021","unstructured":"Albogami Y, Cusi K, Daniels MJ, Wei YJ, Winterstein AG. Glucagon-Like peptide 1 receptor agonists and chronic lower respiratory disease exacerbations among patients with type 2 diabetes. Diabetes Care. 2021;44(6):1344\u201352. https:\/\/doi.org\/10.2337\/dc20-1794","journal-title":"Diabetes Care"},{"issue":"2","key":"1866_CR47","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2337\/diacare.15.2.256","volume":"15","author":"W Marhoffer","year":"1992","unstructured":"Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care. 1992;15(2):256\u201360. https:\/\/doi.org\/10.2337\/diacare.15.2.256. %J Diabetes Care.","journal-title":"Diabetes Care"},{"issue":"7","key":"1866_CR48","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1164\/rccm.202004-0993OC","volume":"203","author":"D Foer","year":"2021","unstructured":"Foer D, Beeler PE, Cui J, Karlson EW, Bates DW, Cahill KN. Asthma exacerbations in patients with type 2 diabetes and asthma on Glucagon-like Peptide-1 receptor agonists. Am J Respir Crit Care Med. 2021;203(7):831\u201340. https:\/\/doi.org\/10.1164\/rccm.202004-0993OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1866_CR49","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41385-020-0262-1","volume":"13","author":"W Choi","year":"2020","unstructured":"Choi W, Choe S, Lin J, Borchers MT, Kosmider B, Vassallo R, et al. Exendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPAR\u03b3-FOXA2-phosphatase signaling. Mucosal Immunol. 2020;13(4):637\u201351. https:\/\/doi.org\/10.1038\/s41385-020-0262-1","journal-title":"Mucosal Immunol"},{"issue":"5","key":"1866_CR50","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jaci.2017.11.043","volume":"142","author":"S Toki","year":"2018","unstructured":"Toki S, Goleniewska K, Reiss S, Zhang J, Bloodworth MH, Stier MT, et al. Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. J Allergy Clin Immunol. 2018;142(5):1515\u2013e15281518. https:\/\/doi.org\/10.1016\/j.jaci.2017.11.043","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1866_CR51","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/cea.14284","volume":"53","author":"D Foer","year":"2023","unstructured":"Foer D, Beeler PE, Cui J, Snyder WE, Mashayekhi M, Nian H, et al. Glucagon-like peptide-1 receptor agonist use is associated with lower serum Periostin. Clin Experimental Allergy: J Br Soc Allergy Clin Immunol. 2023;53(4):469\u201373. https:\/\/doi.org\/10.1111\/cea.14284","journal-title":"Clin Experimental Allergy: J Br Soc Allergy Clin Immunol"},{"issue":"12","key":"1866_CR52","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1210\/en.2013-1666","volume":"154","author":"NE Viby","year":"2013","unstructured":"Viby NE, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Kissow H. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 2013;154(12):4503\u201311. https:\/\/doi.org\/10.1210\/en.2013-1666","journal-title":"Endocrinology"},{"issue":"6","key":"1866_CR53","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1165\/rcmb.2015-0311OC","volume":"55","author":"P Rogliani","year":"2016","unstructured":"Rogliani P, Calzetta L, Capuani B, Facciolo F, Cazzola M, Lauro D, et al. Glucagon-Like peptide 1 receptor: A novel Pharmacological target for treating human bronchial hyperresponsiveness. Am J Respir Cell Mol Biol. 2016;55(6):804\u201314. https:\/\/doi.org\/10.1165\/rcmb.2015-0311OC","journal-title":"Am J Respir Cell Mol Biol"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01866-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01866-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01866-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T05:35:59Z","timestamp":1753680959000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-025-01866-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1866"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01866-7","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used publicly available de-identified data. Ethical approval and informed consent were obtained in each original study. No additional ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"295"}}